Revenue
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Inc. (BEAM)
Price$29.46Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24,000 | $18,000 |
| Research & development | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $103.2M | $54.6M |
| Operating expenses | $523.4M | $479.1M | $554.2M | $399.4M | $444.3M | $132.8M | $75.2M |
| Operating income | −$383.7M | −$415.6M | −$176.5M | −$338.5M | −$392.5M | −$132.8M | −$75.2M |
| Operating margin | −274.57% | −654.25% | −46.73% | −555.61% | −757.01% | −553,166.67% | −417,522.22% |
| EBITDA | −$361.4M | −$393.6M | −$156.5M | −$324.3M | −$385.0M | −$128.0M | −$71.7M |
| EBITDA margin | −258.62% | −619.73% | −41.43% | −532.39% | −742.64% | −533,437.50% | −398,061.11% |
| Net income | −$80.0M | −$376.7M | −$132.5M | −$289.1M | −$370.6M | −$194.6M | −$78.3M |
| Net profit margin | −57.24% | −593.13% | −35.09% | −474.54% | −714.91% | −810,800.00% | −435,144.44% |
| Basic EPSper basic share | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$4.19 | -$14.05 |
| Diluted EPSper diluted share | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$4.19 | -$14.05 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | FMR LLCTenPercentOwner,Other | SellCommon Stock · indirect | 251.5K | $35.26 | $8.87M | 854.6K |
| Jun 25, 2026Form 4 | FMR LLCTenPercentOwner,Other | SellCommon Stock · indirect | 33.4K | $35.12 | $1.17M | 1.11M |
| Apr 1, 2026Form 4 · 10b5-1 | Evans John M.CEO | SellCommon Stock | 30.1K | $24.58 | $739.3K | 1.05M |
| Apr 1, 2026Form 4 · 10b5-1 | Simon AmyChief Medical Officer | SellCommon Stock | 6.7K | $24.58 | $164.7K | 102.7K |
| Apr 1, 2026Form 4 · 10b5-1 | Cavanagh Bethany JSVP, Finance and Treasurer | SellCommon Stock | 3.2K | $24.58 | $79.7K | 51.2K |
Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...